Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of Japanese encephalitis vaccine IC51 (Ixiaro, Jespect) in children and adolescents in non-endemic countries
2009-015595-10Phase 3Completed
- Sponsor
- Intercell AG
- Start
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE), sponsored by Intercell AG. Started Nov 2009; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2009-015595-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015595-10.